Bendamoustine is a bifunctional alkylating agent, which has anti-tumor and cytotoxic effects. 65438+ was developed by Ozegowski and his colleagues at the Experimental Institute of Microbiology in Jena, Germany in the early 1960s. The main mechanism of anti-tumor and cytotoxic effect of this product is that the single-stranded and double-stranded DNA is cross-linked by alkylation, which destroys the function and synthesis of DNA, and also cross-links DNA with protein, protein and protein, thus exerting anti-tumor effect. This product can be used alone or in combination with other antineoplastic drugs to treat malignant tumors, such as Hodgkin's disease, non-Hodgkin's lymphoma, plasmacytoma (multiple myeloma), chronic lymphocytic leukemia (CLL), breast cancer, etc.